We advised the WSE-listed Genomtec S.A. on a prospect-free public offering of the company’s shares carried out under the accelerated bookbuilding procedure (ABB) and a related private placement of the company’s new issue shares.
The public offering comprised 1,237,000 series M new issue shares and 900,000 existing shares of the company, admitted to trading on the regulated market of the WSE, offered by its shareholder, Leonarto Funds SCSp. The shares offered by the shareholder were previously borrowed for this purpose from other shareholders of the company. The public offering was targeted at qualified investors and selected retail investors.
As part of the private placement, the company issued 400,000 N shares, which were subscribed for by Leonarto Funds SCSp in order to reinvest the funds raised from the sale of the company’s shares in the public offering (including the funds used to purchase part of the M shares by the shareholder).
The total value of the public offering and the private placement amounted to PLN 20,296,000.
We supported the company in all legal aspects of the transaction. The scope of advisory services included, in particular, advice on structuring the transaction, preparation and negotiation of transaction documentation (e.g. investment agreement, loan agreements, issue documentation), advice on fulfilment of the Company’s disclosure obligations and legal advice on the process of dematerialisation of new issue shares and admission of series M shares to trading on the regulated market of the WSE.
Bookkeeping for the shares offered in the public offering was entrusted to Dom Maklerski INC S.A.. In terms of Investor Relations, the company was also supported by cc group.
We would like to thank Genomtec S.A. and the other advisers involved in the transaction for their fruitful cooperation and trust.
Genomtec S A. is a technology company operating in the field of clinical diagnostics. It was founded in 2016 in Wrocław, Poland, with a vision of international expansion based on a unique mobile genetic diagnostics platform using a patented non-contact heating and detection system. The company, founded by a group of scientists with experience and competence in the fields of molecular biology and microsystems and photonics, has its headquarters and laboratories in Wrocław. Genomtec also has an office in the UK, where part of the international research and engineering team is located.
Lawyers involved in the project
They may interest you
We advised the partners of User.com sp. z o.o. and Vercom S.A.
We advised the partners of User.com sp. z o.o., viz: Grzegorz Warzecha - the founder, and Vercom S.A. - which is a financial investor, on the transaction concerning the...
We advised Webcon on the MCI fund’s investment.
GESSEL provided legal and tax support to Webcon and its founders on the investment by the MCI fund, which acquired a 65.05 percent stake in Webcon, assuming the position...